Laboratorio de Investigación en Genómica, Genética y Bioinformática, Hospital Infantil de México, Federico Gómez, Ciudad de México, Mexico; Departamento de Ciencias Naturales, Unidad Cuajimalpa, Universidad Autónoma Metropolitana, Ciudad de México, Mexico.
Drug Discov Today. 2021 Aug;26(8):2025-2035. doi: 10.1016/j.drudis.2021.06.005. Epub 2021 Jun 18.
The limitations of conventional diagnostic procedures, such as real-time PCR-based methods and serological tests, have led the scientific community to innovate alternative nucleic acid detection approaches for SARS-CoV-2 RNA, thereby addressing the dire need for increased testing. Such approaches aim to provide rapid, accurate, cost-effective, sensitive, and high-throughput detection of SARS-CoV-2 RNA, on multiple specimen types, and without specialized equipment and expertise. The CRISPR-Cas13 system functions as a sequence-specific RNA-sensing tool that has recently been harnessed to develop simplified and flexible testing formats. This review recapitulates technical advances in the most recent CRISPR-Cas13-based methods for SARS-CoV-2/COVID-19 diagnosis. The challenges and opportunities for implementing mass testing using these novel CRISPR-Cas13 platforms are critically analyzed.
传统诊断程序的局限性,如基于实时 PCR 的方法和血清学检测,促使科学界创新用于 SARS-CoV-2 RNA 的替代核酸检测方法,从而满足对更多检测的迫切需求。这些方法旨在提供针对 SARS-CoV-2 RNA 的快速、准确、具有成本效益、灵敏和高通量检测,可用于多种标本类型,且无需专门的设备和专业知识。CRISPR-Cas13 系统作为一种序列特异性 RNA 感应工具,最近已被用于开发简化和灵活的检测格式。本综述总结了最近用于 SARS-CoV-2/COVID-19 诊断的基于 CRISPR-Cas13 的方法的技术进展。批判性地分析了使用这些新型 CRISPR-Cas13 平台进行大规模检测的挑战和机遇。